Armando Lira Pineda

Lipoprotein (a) variability in high cardiovascular risk individuals with hypertriglyceridemia and controlled LDL-C on statin therapy in REDUCE-IT

Michael Szarek, Deepak L. Bhatt, Michael Miller, Eliot A. Brinton et autres

BACKGROUND: Although repeated testing of lipoprotein(a) [Lp(a)] is generally not recommended because of the genetically determined nature of concentrations, reports of significant intraindividual variability in serial assessments have challenged the single lifetime measurement framework. OBJECTIVE: To determine sources of Lp(a) variability among …

us, ca, fr (code pays fourni par la source)

RISK-WEIGHTED APOB OUTPERFORMS TRADITIONAL LIPID BIOMARKERS IN PREDICTING RESIDUAL CARDIOVASCULAR RISK IN STATIN-TREATED HYPERTRIGLYCERIDEMIC PATIENTS: POST HOC ANALYSIS OF THE REDUCE-IT PLACEBO ARM

Michaela Rehman, Elias Björnson, Deepak Bhatt, Philippe Gabriel Steg et autres

26-A-13752-ACC EFFICACY OF ICOSAPENT ETHYL AMONG PATIENTS AT EXTREME CARDIOVASCULAR RISK: A SECONDARY ANALYSIS OF REDUCE-IT

Rahul Aggarwal, Deepak L Bhatt, Michael S. Miller, Eliot A. Brinton et autres

us (code pays fourni par la source)

Icosapent ethyl reduces CVD risk in cardiovascular-kidney-metabolic syndrome: REDUCE-IT CKM

Michael Miller, Deepak L. Bhatt, Eliot A. Brinton, Terry A. Jacobson et autres

Background/Introduction: Cardiovascular-kidney-metabolic (CKM) syndrome was recently identified as a cardiometabolic disorder that incorporates chronic kidney disease with the metabolic syndrome (MetS). REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial) was an international, double-blind, placebo-controlled trial that randomized hypertriglyceridemic (TG, 150-499 mg/dL) …

us, ca (code pays fourni par la source)

Benefit of icosapent ethyl across types and sizes of myocardial infarction in REDUCE-IT

Chen Gurevitz, Deepak L. Bhatt, Robert P. Giugliano, Philippe Gabríel Steg et autres

AIMS: We studied the efficacy and safety of icosapent ethyl (IPE) 4g daily in reducing the risk of myocardial infarction (MI) across different MI subtypes and sizes, among REDUCE-IT high-risk patients with hypertriglyceridemia. METHODS: REDUCE-IT was a phase 3b, double-blind multicenter trial. …

us, fr, ar, ca, nl (code pays fourni par la source)

Abstract 4140394: Substantial cardiovascular risk reduction with icosapent ethyl in patients with prior cardiovascular events regardless of coronary artery disease history: REDUCE-IT CAD

Rahul Aggarwal, Deepak L. Bhatt, Christie M. Ballantyne, Michael Miller et autres

BACKGROUND: REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial) was a multinational, double-blind trial that randomized 8,179 statin-treated patients with controlled low-density lipoprotein cholesterol, elevated triglycerides, and cardiovascular (CV) risk, to icosapent ethyl (IPE) 4 g daily or placebo. Randomization was …

us, ca, fr (code pays fourni par la source)

ICOSAPENT ETHYL REDUCES MACE IN PATIENTS WITH ELEVATED TRIGLYCERIDES AND HIGH OR LOW LIPOPROTEIN(A) CONCENTRATIONS: A REDUCE-IT SUBANALYSIS

Michael Szarek, Deepak L. Bhatt, Eliot A. Brinton, Michael Miller et autres

us (code pays fourni par la source)

Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl

Michael Szarek, Deepak L. Bhatt, Michael Miller, Eliot A. Brinton et autres

BACKGROUND: Elevated lipoprotein(a) (Lp[a]) concentrations are associated with increased cardiovascular event risk even in the presence of well-controlled low-density lipoprotein cholesterol levels, but few treatments are documented to reduce this residual risk. OBJECTIVES: The aim of this post hoc analysis of REDUCE-IT …

us, ca, fr (code pays fourni par la source)

Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial

Neila Sayah, Deepak L. Bhatt, Michael Miller, Eliot A. Brinton et autres

The REDUCE-IT [Reduction of Cardiovascular Events With Icosapent Ethyl (IPE)-Intervention Trial] trial showed robust reductions in ischaemic events with IPE vs. placebo, including reduced cardiovascular (CV) death, albeit with increased rates of bleeding, and of atrial fibrillation (AF).1 These observations were confirmed …

fr, us, ca (code pays fourni par la source)

Abstract 12542: Effectiveness of Icosapent Ethyl on First and Total Cardiovascular Events in the Metabolic Syndrome: REDUCE-IT MetSyn

Michael Miller, Deepak L. Bhatt, Eliot A. Brinton, Terry A. Jacobson et autres

Introduction: The Metabolic Syndrome (MetSyn) is associated with persistently high risk of cardiovascular (CV) events despite statin treatment. Methods: REDUCE-IT was a multinational, double-blind trial that randomized 8179 high CV risk statin-treated patients with controlled low density lipoprotein cholesterol, and elevated triglycerides, …

us, fr, ca (code pays fourni par la source)

Eicosapentaenoic acid, arachidonic acid, and triglyceride levels mediate most of the benefit of icosapent ethyl in REDUCE-IT

Michael Szarek, Deepak L. Bhatt, Michael Miller, Philippe Gabríel Steg et autres

Abstract Background In REDUCE-IT, icosapent ethyl (IPE) reduced major adverse cardiovascular (CV) events (MACE) relative to placebo (PBO) in 8179 statin-treated patients with residual hypertriglyceridemia and high CV risk. Questions have been raised about the mechanisms of benefit of IPE and the …

us, fr, ca (code pays fourni par la source)

Effectiveness of icosapent ethyl on first and total cardiovascular events in patients with metabolic syndrome, but without diabetes: REDUCE-IT MetSyn

Michael Miller, Deepak L. Bhatt, Eliot A. Brinton, Terry A. Jacobson et autres

Abstract Aims Metabolic syndrome (MetSyn) is associated with high risk of cardiovascular (CV) events, irrespective of statin therapy. In the overall REDUCE-IT study of statin-treated patients, icosapent ethyl (IPE) reduced the risk of the primary composite endpoint (CV death, non-fatal myocardial infarction, …

us, fr, ca (code pays fourni par la source)